Content:
Antivirals
Content on this page:
Antivirals
Cough & Cold Preparations
Vaccines, Antisera & Immunologicals
Disclaimer
Related MIMS Drugs
Content on this page:
Antivirals
Cough & Cold Preparations
Vaccines, Antisera & Immunologicals
Disclaimer
Related MIMS Drugs
Antivirals
| Drug | Dosage | Remarks |
| Ribavirin | 20 mg/mL via inhalation delivered over 12-18 hourly for at least 3 days Max duration: 7 days Use a small particle aerosol generator (SPAG) to administer the drug Carefully selected hospitalized infants and young children: 100 mg PO 6 hourly x 5 days |
Adverse Reactions
|
Cough & Cold Preparations
| Drug | Dosage | Remarks |
| Acetylcysteine | 1-2 years old: 100 mg PO 24 hourly 2-6 years old: 200-400 mg PO 24 hourly x 5-10 days |
Adverse Reactions
|
| Ambroxol | 2-5 years old: 7.5-15 mg PO 8 hourly 6-12 years old: 15-30 mg PO 8-12 hourly ≥12 years old: 60-120 mg PO 8-12 hourly |
Adverse Reactions
|
| Cyclidrol | >2 years old: 80 mg PO 12 hourly | Adverse Reactions
|
| Dextromethorphan | 6-<12 years old: 15 mg PO 6-8 hourly ≥12 years old: 10-20 mg PO 4-6 hourly |
Adverse Reactions
|
| Dried ivy leaf extract | Syr: 1-5 years old: 2.5 mL PO 8 hourly 6-10 years old: 5 mL PO 8 hourly Effervescent tab: 6-12 years old: 32.5 mg PO 12 hourly |
Adverse Reactions
|
| Erdosteine |
15-<20 kg: 175 mg PO 12 hourly 20-30 kg: 175 mg PO 8 hourly >30 kg: 300 mg PO 12 hourly |
Adverse Reactions
|
Vaccines, Antisera & Immunologicals
| Drug | Dosage | Remarks |
| Nirsevimab | Neonates and infants <5 kg: 50 mg IM as a single dose Neonates and infants ≥5 kg: 100 mg IM as a single dose |
Adverse Reactions
|
| Palivizumab | 15 mg/kg IM once monthly during RSV season Max dose: 3 doses for patients without significant heart/lung disease born 32-34 6/7 weeks; 5 doses for others |
Adverse Reactions
|
| RSV-Ig | Adolescents: 0.5 mL IM as a single dose | Adverse Reactions
|
Disclaimer
All dosage recommendations are for children with normal renal and hepatic function unless otherwise stated.
Not all products are available or approved for above use in all countries.
Products listed in the Drug Summary are based on indications stated in the locally approved product monographs.
Please refer to local product monographs in Related MIMS Drugs for country-specific prescribing information.
Not all products are available or approved for above use in all countries.
Products listed in the Drug Summary are based on indications stated in the locally approved product monographs.
Please refer to local product monographs in Related MIMS Drugs for country-specific prescribing information.
